VPT:CC - Ventripoint's AI Heart Technology Takes Centre Stage In ITN Business The Hidden Heart Programme
(TheNewswire)
Toronto, Ontario – TheNewswire –September 28, 2023 - Ventripoint DiagnosticsLtd. (" Ventripoint " or the " Company "),(TSXV:VPT ) ( OTC:VPTDF), a company using AI to create diagnostic heartimages, is thrilled to announce it will befeatured in an international news-style programme, “The HiddenHeart”, made possible by the British Heart Foundation and ITNBusiness.
The programme, which documents how Ventripointtransforms ultrasound images into 3D models of the heart and providescardiac metrics with an accuracy comparative to cardiac MRI, islaunching on World Heart Day, September 29 th . Ventripointis one of a handful of technologies chosen to demonstrate innovationsin treating heart disease.
“Ventripoint’s mission is to use AI to improvepatients’ lives by giving cardiologists another diagnostic tool,” said Dr. Alvira Macanovic, President & CEOof Ventripoint Diagnostics.
“I want to thank the British Heart Foundation and ITNBusiness for sharing this story on ITVX, which has reached more than 2billion viewers since its launch. We hope the audience will see the AIinnovation we are bringing to clinical practiceto improve patient care and treatment outcomes.”
The programme can be viewed on ITN video-on-demandservice and will also be hosted on the British Heart Foundationwebsite, allowing easy access to “The Hidden Heart”. To watch the full programme, visit:https://www.bhf.org.uk/hiddenheart.
The Hidden Heart was made to raise awareness of heartconditions and highlight the innovations and research underway totreat conditions such as congenital heart disease, heart attacks,heart failure and transplants. Identifying risk factors and earlydetection is an important part of the programme’s messaging.
Ventripoint’s feature in this programme willhighlight the use of Ventripoint’s AI technology, branded VMS+, anddemonstrate how it works, as well as the benefits of this accessibletechnology to practitioners and patients. Ventripoint can be used inhospitals and clinics. Within minutes it produces MRI quality 3Dimages at a fraction of the cost and time of an MRI. This offers thepossibility of offering physicians and patients wider access todiagnostic imaging to treat heart disease and conditions in infants,children, and adults.
This “Hidden Heart” will bring attention to theprominence of heart disease, especially hidden heart disease, to themillions that suffer from this issue worldwide. There are around 7.6million people in the UK alone living with a heart or circulatorydisease, as well as many more who are not yet aware of their owncardiac condition.
The ITV programme focuses on the prominence ofcardiac conditions in the UK, with one in four people diagnosed withheart disease.
“This highlights the importance of early detectionand is an opportunity for Ventripoint to demonstrate the need for itstechnology and further expand its presence in the UK market,” addedDr. Macanovic. The Ventripoint VMS+ is currently being routinelyused by Evelina London Children’s Hospital and East MidlandsCongenital Heart Center at the Leicester Royal Infirmary in theUK.
The programme also highlights the important work BHF isdoing and will encourage those who are at risk of cardiac relatedissues to seek proper assessment. An individual’s decision toinvestigate their health can save one’s life and will ultimatelyfulfill the mission of the “The Hidden Heart” and Ventripoint.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
About British Heart Foundation
The British Heart Foundation is a cardiovascularresearch charity in the UK that funds medical research and raisesawareness for heart and circulatory diseases. BHF funds over 100million pounds into research each year for heart and circulatoryrelated diseases. The foundation works to benefit those who sufferfrom cardiac related illness, their loved ones, as well as anyone withrisk factors for developing these diseases.
About ITN
The Independent Television News (ITN) Business is aUK-based media production and broadcast journalist company. ITN’scontent portfolio includes broadcast news, documentaries, films,sports, education, and more. It’s streaming platform, ITVX, hasreach around the world and has surpassed two billion downloads sinceits launch in December 2022.
For further information, pleasecontact:
Jonathan Robinson
416-669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.